Editorial: clinical outcomes in lean NAFLD-the devil is in the details
- PMID: 37053487
- DOI: 10.1111/apt.17449
Editorial: clinical outcomes in lean NAFLD-the devil is in the details
Comment in
-
Editorial: clinical outcomes in lean NAFLD - the devil is in the details. Authors' reply.Aliment Pharmacol Ther. 2023 May;57(9):1042-1043. doi: 10.1111/apt.17453. Aliment Pharmacol Ther. 2023. PMID: 37053482 Free PMC article. No abstract available.
Comment on
-
Higher mortality among lean patients with non-alcoholic fatty liver disease despite fewer metabolic comorbidities.Aliment Pharmacol Ther. 2023 May;57(9):1014-1027. doi: 10.1111/apt.17424. Epub 2023 Feb 23. Aliment Pharmacol Ther. 2023. PMID: 36815445 Free PMC article.
References
REFERENCES
-
- Teng ML, Ng CH, Huang DQ, Chan KE, Tan DJ, Lim WH, et al. Global incidence and prevalence of non-alcoholic fatty liver disease. Clin Mol Hepatol. 2023;29(Suppl):S32-42. https://doi.org/10.3350/cmh.2022.0365
-
- Powell EE, Wong VW-S, Rinella M. Non-alcoholic fatty liver disease. Lancet. 2021;397:2212-24.
-
- Huang DQ, Downes M, Evans RM, Witztum JL, Glass CK, Loomba R. Shared mechanisms between cardiovascular disease and NAFLD. Semin Liver Dis. 2022;42:455-64.
-
- Tan DJH, Setiawan VW, Ng CH, Lim WH, Muthiah MD, Tan EX, et al. Global burden of liver cancer in males and females: changing etiological basis and the growing contribution of NASH. Hepatology. 2023;57:77(4):1150-63. https://doi.org/10.1002/hep.32758
-
- Ye Q, Zou B, Yeo YH, Li J, Huang DQ, Wu Y, et al. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5:739-52.
Publication types
MeSH terms
LinkOut - more resources
Medical